Fate Therapeutics (FATE) Misses Q4 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. ACCV
4. LLY
5. FLG
6. META
7. FICO
8. GMAB
9. QQQ
10. TSLA

Go back to Fate Therapeutics (FATE) Misses Q4 EPS by 5c

Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational Progress

February 28, 2022 4:01 PM EST

Enrollment Ongoing in Multi-dose, Multi-cycle Escalation Cohort of FT596+R at 900 Million Cells per Dose for R/R BCL; Interim Phase 1 Data of 16 Patients Showed 69% ORR and 56% CR in Single-dose Escalation Cohorts of FT596+R at 90 Million Cells

Granted RMAT Designation for FT516 in R/R DLBCL; Enrollment Ongoing in Multi-dose, Multi-cycle Expansion Cohorts at 900 Million Cells per Dose in Disease-specific Indications, including Aggressive BCL in Patients Previously Treated with Autologous CD19-targeted CAR T-cell Therapy

Initial FT819 Dose-Escalation Cohort Cleared with No DLTs for R/R BCL in Landmark Phase... More